@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Citius

Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.

Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today. We're beginning to believe (and...

Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.

Here's How Provention's Treatment Works. Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.

Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.

The 2021 Biotech Six Pack: Stocks We Expect to Double! These are ideas #3 and #4 for the 'Biotech...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
Citius, Leonard Mazur

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS

Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy

VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...

Citius Pharma (CTXR) Updates Shareholders.

Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
hapbee

Adding Hapbee Tech (HAPB, HAPBF) $0.34 to Biotech Six Pack Watch List.

UPDATE ON BIOTECH SIX PACK, SIX STOCKS WE EXPECT TO DOUBLE. While the Biotech Stock Review was launched...

Latest article

Smart for Life (SMFL) Capitulates?

We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....

Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%

Nearly 100 Alzheimer’s programs have failed in the past decade. Biotech investors should study or at least become...

Novogratz Remains Steadfast on Crypto, Says Wait Until Next Year (Bloomberg)

Great call. This was actually from Late 2018. (Bloomberg) — Billionaire investor Michael Novogratz is resolute when it...